RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $70
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Kendall Au maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $70.
RBC Capital analyst Kendall Au maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $70.